免疫检查点表达模式在T细胞子集在轻链氨基粉症:VISTA,PD-1和TIGIT作为潜在的治疗点
Jinghua Wang1, Yujie Zhao2, Pengjun Liao1
1Department of Hematology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.
Blood science (Baltimore, Md.)
|January 16, 2024
概括
粉样蛋白轻链粉样蛋白症患者在周围血液中显示T细胞免疫检查点增加,V域免疫球蛋白抑制T细胞激活 (VISTA) 和编程细胞死亡1 (PD-1). 这些升高的检查点与脏损伤相关,表明潜在的治疗点.
科学领域:
- 免疫学 免疫学 免疫学
- 血液学 血液学 血液学
- 在瘤学瘤学.
背景情况:
- 粉样蛋白轻链 (AL) 粉样蛋白症是一种罕见的,激进的血细胞疾病.
- 了解AL Amyloidosis中的T细胞免疫格局对于预后和治疗至关重要.
- 免疫检查点调节失调可能会导致AL氨基粉症的免疫抑制环境.
研究的目的:
- 为了研究T细胞免疫检查点表达模式在全身AL氨基粉症.
- 探索免疫检查点和临床生物学特征之间的关系.
- 为了确定AL氨基粉症的潜在治疗点.
主要方法:
- 流细胞计用于分析T细胞子集.
- 量化了V-域免疫球蛋白抑制T细胞激活 (VISTA),编程细胞死亡1 (PD-1),T细胞免疫球蛋白和含粘素域-3 (Tim-3) 以及具有Ig和ITIM域 (TIGIT) 表达的T细胞免疫受体.
- 分析了来自19名新诊断的AL粉样症患者和健康个体的外周血液和骨髓样本.
主要成果:
- 与健康个体相比,AL粉样化症患者在周围血液中表现出显著更高的VISTA+和PD-1+T细胞百分比.
- 增加的PD-1+和TIGIT+T细胞与AL氨基粉症患者的脏参与有关.
- 包括调控性T细胞 (Tregs) 在内的PD-1+ T细胞子集与蛋白尿水平正相关.
结论:
- 这项研究揭示了AL氨基粉症中VISTA和PD-1T细胞的升高,表明免疫抑制状态.
- 增加PD-1和TIGIT表达与AL氨基粉症的损伤有关.
- 维斯塔,PD-1和TIGIT代表了AL氨基粉症中T细胞耗尽的有希望的治疗点.
相关概念视频
Tumor Immunotherapy
527
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
527
T Cell Activation and Clonal Selection
739
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
Naive T cells that have not yet encountered an antigen express two primary CD...
739


